Compare LZM & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZM | ASMB |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Isle of Man | United States |
| Employees | 142 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 385.4M | 440.0M |
| IPO Year | N/A | 2010 |
| Metric | LZM | ASMB |
|---|---|---|
| Price | $4.00 | $29.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 306.9K | 60.4K |
| Earning Date | 03-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $86.37 | N/A |
| Revenue Next Year | $202.49 | $235.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.90 | $8.15 |
| 52 Week High | $6.23 | $39.71 |
| Indicator | LZM | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 56.76 |
| Support Level | $3.60 | $29.31 |
| Resistance Level | $4.38 | $30.54 |
| Average True Range (ATR) | 0.27 | 1.51 |
| MACD | 0.11 | 0.17 |
| Stochastic Oscillator | 84.68 | 92.75 |
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining and to become an emerging supplier of responsibly sourced, lower-carbon and lower-sulfur dioxide emission metals to the battery, EV, and hydrogen markets modern pre-development exploration-stage metals company. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.